This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commercial formulation, under single-dose and steady-state conditions in male subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
36
Administered subcutaneously (s.c., under the skin)
Unnamed facility
Neuss, Germany
Area under the glucose infusion rate curve
Time frame: 0-24 hours after dosing
Maximum glucose infusion rate (GIRmax)
Time frame: 0-24 hours after dosing
Time to maximum glucose infusion rate (tGIRmax)
Time frame: 0-24 hours after dosing
Area under the serum insulin degludec curve
Time frame: 0-96 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.